查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1968627

FC 和糖基工程抗体市场分析及预测至 2035 年：按类型、产品类型、服务、技术、应用、最终用户、製程、功能、安装类型、模式

FC and Glycoengineered Antibodies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Functionality, Installation Type, Mode
出版日期: | 出版商: Global Insight Services | 英文 370 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计Fc区及糖基化修饰抗体市场将从2024年的367亿美元成长至2034年的2,796亿美元，复合年增长率约为22.5%。 Fc区及糖基化修饰抗体市场涵盖旨在透过Fc区修饰和糖基化工程提高抗体疗效的疗法。这些抗体能够增强与免疫系统的相互作用，进而提高对癌症、自体免疫疾病和感染疾病的治疗效果。这些疾病的日益普遍以及生物技术的进步正在推动市场成长，并促进以精准医疗和个人化治疗方案为重点的创新。

在治疗应用和精准医疗的推动下，Fc 和糖基化修饰抗体市场预计将迎来显着成长。单株抗体市场表现良好，这得益于其靶向癌细胞的特异性和疗效。在该领域，糖基化修饰抗体因其增强的免疫反应和降低的免疫抗原性而备受关注。生物相似药是表现第二好的领域，这反映了其成本效益和在医疗保健系统中日益增长的接受度。在各个细分领域中，肿瘤领域仍然是表现最佳的领域，这主要得益于癌症发生率的上升和对标靶治疗的需求。自体免疫疾病领域也经历了显着增长，这主要得益于对创新治疗方法以应对复杂免疫疾病的需求。糖基化修饰和 Fc 受体调控技术的进步正在为新的治疗选择铺平道路。製药公司之间的策略联盟和合作正在推动创新并拓展治疗范围。预计市场将受益于持续的研发工作，这些工作旨在提高抗体疗效和改善患者预后。

市场区隔
类型 Fc工程化抗体、糖基工程化抗体
产品 单株抗体、多株抗体、生物相似药
服务 合约研究、契约製造、咨询
科技 重组DNA技术、融合瘤技术、噬菌体展示技术
应用领域 肿瘤学、自体免疫疾病、感染疾病、心血管疾病、神经系统疾病
最终用户 製药公司、生技公司、研究机构、合约研究组织
过程 上游工程，下游过程
功能 治疗、诊断与研究
安装表格 内部安装、外包
管理路线 静脉注射和皮下注射

市场概况：

受策略性定价和创新产品上市的驱动，FC和糖基化抗体市场正经历市场份额的动态变化。大型製药公司正利用先进的糖基化技术来提高抗体的治疗效果并建立竞争优势。该市场的特点是拥有强大的新产品平臺，专注于个人化医疗和标靶治疗。这种创新正在推动竞争格局的形成，各公司透过策略联盟和收购争夺主导。竞争基准分析显示，该市场由少数几家大型企业主导，但新兴生技公司正快速崛起。监管因素，特别是北美和欧洲的严格监管规定，对塑造市场动态、确保安全性和有效性至关重要。在生物技术进步和单株抗体需求不断增长的推动下，该市场呈现出成长迹象。然而，高昂的研发成本和复杂的监管路径等挑战依然存在，需要进行策略规划并增加研发投入。

主要趋势和驱动因素：

受生物技术进步和标靶治疗需求不断增长的推动，FC和糖基化抗体市场正经历强劲成长。关键趋势包括开发具有更高疗效和更低免疫抗原性的新一代抗体。这些创新正为癌症和自体免疫疾病的更有效治疗方法铺平道路。此外，个人化医疗日益受到关注，针对每位患者量身定制的抗体疗法也越来越普及。基因和生物标记研究的进展为这一转变提供了支持。对精准医疗的日益重视是关键驱动因素，有望改善病患疗效并减少副作用。此外，生物相似药的兴起正在重塑市场格局，为传统生物製药提供更具成本效益的替代方案。监管机构对生物相似药开发的支持也进一步加速了市场扩张。新兴市场蕴藏着许多机会，这些市场的医疗基础设施正在不断完善，获得先进疗法的机会也不断增加。投资研发和策略合作的公司将占据有利地位，充分利用这些趋势。

限制与挑战：

目前，FC和糖基化抗体市场面临许多重大限制和挑战。其中一个关键限制因素是这些先进抗体复杂的高成本生产工艺，这可能会阻碍中小企业进入市场。这种复杂性通常会导致更高的生产成本，从而限制产品的普及和广泛应用。此外，监管障碍也构成重大挑战。这些生物製药产品所需的严格核准流程可能会延迟市场准入并增加研发成本。此外，缺乏熟悉Glico的专业人员也是市场面临的一大挑战，这可能会阻碍研发活动。智慧财产权问题也构成重大障碍。专利纠纷可能会出现，潜在的法律诉讼可能会扼杀创新。最后，市场还必须应对来自传统单株抗体的竞争。传统抗体的根深蒂固的地位可能会限製Glico抗体替代品的市场份额。这些挑战共同塑造了市场的成长轨迹。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • Fc工程抗体
    • 糖基工程抗体
  • 市场规模及预测：依产品划分
    • 单株抗体
    • 多株抗体
    • 生物相似药
  • 市场规模及预测：依服务划分
    • 委託研究
    • 契约製造
    • 咨询
  • 市场规模及预测：依技术划分
    • 重组DNA技术
    • 融合瘤技术
    • 噬菌体展示技术
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 自体免疫疾病
    • 感染疾病
    • 心血管疾病
    • 神经系统疾病
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究所
    • CRO
  • 市场规模及预测：依製程划分
    • 上游工程
    • 下游工艺
  • 市场规模及预测：依功能划分
    • 治疗
    • 诊断
    • 调查
  • 市场规模及预测：依安装类型划分
    • 内部开发
    • 外包
  • 市场规模及预测：按模式
    • 静脉注射
    • 皮下注射

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Glycotope
  • Argenx
  • Xencor
  • Mabwell
  • ImmunoGen
  • MacroGenics
  • Alector
  • Zymeworks
  • Alligator Bioscience
  • MorphoSys
  • Sorrento Therapeutics
  • Genmab
  • Crescendo Biologics
  • Harbour BioMed
  • BioAtla

第九章：关于我们

简介目录
Product Code: GIS33866

FC and Glycoengineered Antibodies Market is anticipated to expand from $36.7 billion in 2024 to $279.6 billion by 2034, growing at a CAGR of approximately 22.5%. The FC and Glycoengineered Antibodies Market encompasses therapeutics designed to enhance antibody efficacy through Fc region modifications and glycosylation engineering. These antibodies improve immune system engagement and therapeutic outcomes, targeting cancer, autoimmune diseases, and infectious conditions. Rising prevalence of such diseases and advances in biotechnology fuel market growth, with innovations focusing on precision medicine and personalized treatment approaches.

The FC and Glycoengineered Antibodies Market is poised for substantial growth, propelled by advancements in therapeutic applications and precision medicine. The monoclonal antibodies segment leads in performance, driven by their specificity and efficacy in targeting cancer cells. Within this segment, glycoengineered antibodies are gaining prominence due to enhanced immune response and reduced immunogenicity. Biosimilar antibodies follow as the second-highest performing segment, reflecting cost-effectiveness and increasing acceptance in healthcare systems. Among sub-segments, oncology remains the top-performing area, given the rising prevalence of cancer and demand for targeted therapies. The autoimmune diseases sub-segment is also witnessing significant growth, supported by the need for innovative treatments addressing complex immune disorders. Technological advancements in glycoengineering and Fc receptor modulation are paving the way for novel therapeutic options. Strategic partnerships and collaborations among pharmaceutical companies are fostering innovation and expanding the therapeutic landscape. The market is set to benefit from ongoing research and development efforts, enhancing antibody efficacy and patient outcomes.

Market Segmentation
TypeFc Engineered Antibodies, Glycoengineered Antibodies
ProductMonoclonal Antibodies, Polyclonal Antibodies, Biosimilars
ServicesContract Research, Contract Manufacturing, Consulting
TechnologyRecombinant DNA Technology, Hybridoma Technology, Phage Display Technology
ApplicationOncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, CROs
ProcessUpstream Process, Downstream Process
FunctionalityTherapeutic, Diagnostic, Research
Installation TypeIn-house, Outsourced
ModeIntravenous, Subcutaneous

Market Snapshot:

The FC and Glycoengineered Antibodies Market is witnessing dynamic shifts in market share, driven by strategic pricing and innovative product launches. Leading pharmaceutical companies are leveraging advanced glycoengineering techniques to enhance the therapeutic efficacy of antibodies, resulting in a competitive edge. The market is characterized by a robust pipeline of new products, with a focus on personalized medicine and targeted therapies. This innovation is fostering a competitive landscape, where companies are vying for dominance through strategic collaborations and acquisitions. Competition benchmarking reveals a landscape dominated by a few key players, yet emerging biotech firms are rapidly gaining traction. Regulatory influences, particularly in North America and Europe, are pivotal in shaping market dynamics, with stringent guidelines ensuring safety and efficacy. The market is poised for growth, driven by advancements in biotechnology and increasing demand for monoclonal antibodies. However, challenges such as high development costs and complex regulatory pathways persist, necessitating strategic planning and investment in R&D.

Geographical Overview:

The market for FC and glycoengineered antibodies is witnessing notable growth across various regions, each with unique characteristics. North America stands at the forefront, propelled by advanced biotechnology infrastructure and substantial R&D investments. The region's robust healthcare sector further catalyzes market expansion, with the United States playing a pivotal role in driving innovation and development. Europe follows closely, showcasing a strong focus on biopharmaceutical advancements and strategic collaborations. Countries such as Germany and the United Kingdom are emerging as key players, fostering a conducive environment for market growth. The region's commitment to healthcare innovation enhances its market potential. In Asia Pacific, the market is experiencing rapid expansion, fueled by increasing healthcare expenditures and technological advancements. China and Japan are leading the charge, with significant investments in antibody research and development. Latin America and the Middle East & Africa are emerging markets, with growing interest in biopharmaceuticals and antibody technologies.

Key Trends and Drivers:

The FC and Glycoengineered Antibodies Market is experiencing robust growth, driven by advancements in biotechnology and increasing demand for targeted therapeutics. Key trends include the development of next-generation antibodies with enhanced efficacy and reduced immunogenicity. These innovations are paving the way for more effective treatments in oncology and autoimmune diseases. Moreover, personalized medicine is gaining traction, with tailored antibody therapies becoming more prevalent. This shift is supported by advancements in genetic and biomarker research. The growing focus on precision medicine is a significant driver, as it promises improved patient outcomes and reduced side effects. Additionally, the rise of biosimilars is reshaping the market landscape, offering cost-effective alternatives to traditional biologics. Regulatory support for biosimilar development is further accelerating market expansion. Opportunities abound in emerging markets, where healthcare infrastructure is improving, and access to advanced therapies is increasing. Companies investing in R&D and strategic collaborations are well-positioned to capitalize on these trends.

Restraints and Challenges:

The FC and Glycoengineered Antibodies Market is currently navigating several significant restraints and challenges. A primary constraint is the intricate and costly manufacturing processes associated with these advanced antibodies, which can deter smaller companies from entering the market. This complexity often results in higher production costs, which can limit accessibility and adoption. Additionally, regulatory hurdles present a formidable challenge. The rigorous approval processes required for these biopharmaceuticals can delay market entry and increase development costs. Furthermore, the market faces a shortage of skilled professionals adept in glycoengineering, which can impede research and development efforts. Intellectual property issues also pose a significant barrier. Patent disputes can arise, leading to potential legal battles that can stall innovation. Lastly, the market must contend with competition from traditional monoclonal antibodies, which, due to their established presence, can limit the market share of glycoengineered alternatives. These challenges collectively shape the market's growth trajectory.

Key Players:

Glycotope, Argenx, Xencor, Mabwell, ImmunoGen, MacroGenics, Alector, Zymeworks, Alligator Bioscience, MorphoSys, Sorrento Therapeutics, Genmab, Crescendo Biologics, Harbour BioMed, BioAtla

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Installation Type
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Fc Engineered Antibodies
    • 4.1.2 Glycoengineered Antibodies
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Monoclonal Antibodies
    • 4.2.2 Polyclonal Antibodies
    • 4.2.3 Biosimilars
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Research
    • 4.3.2 Contract Manufacturing
    • 4.3.3 Consulting
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Recombinant DNA Technology
    • 4.4.2 Hybridoma Technology
    • 4.4.3 Phage Display Technology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Autoimmune Diseases
    • 4.5.3 Infectious Diseases
    • 4.5.4 Cardiovascular Diseases
    • 4.5.5 Neurological Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 CROs
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Process
    • 4.7.2 Downstream Process
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Therapeutic
    • 4.8.2 Diagnostic
    • 4.8.3 Research
  • 4.9 Market Size & Forecast by Installation Type (2020-2035)
    • 4.9.1 In-house
    • 4.9.2 Outsourced
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Intravenous
    • 4.10.2 Subcutaneous

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Functionality
      • 5.2.1.9 Installation Type
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Functionality
      • 5.2.2.9 Installation Type
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Functionality
      • 5.2.3.9 Installation Type
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Functionality
      • 5.3.1.9 Installation Type
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Functionality
      • 5.3.2.9 Installation Type
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Functionality
      • 5.3.3.9 Installation Type
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Functionality
      • 5.4.1.9 Installation Type
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Functionality
      • 5.4.2.9 Installation Type
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Functionality
      • 5.4.3.9 Installation Type
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Functionality
      • 5.4.4.9 Installation Type
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Functionality
      • 5.4.5.9 Installation Type
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Functionality
      • 5.4.6.9 Installation Type
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Functionality
      • 5.4.7.9 Installation Type
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Functionality
      • 5.5.1.9 Installation Type
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Functionality
      • 5.5.2.9 Installation Type
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Functionality
      • 5.5.3.9 Installation Type
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Functionality
      • 5.5.4.9 Installation Type
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Functionality
      • 5.5.5.9 Installation Type
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Functionality
      • 5.5.6.9 Installation Type
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Functionality
      • 5.6.1.9 Installation Type
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Functionality
      • 5.6.2.9 Installation Type
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Functionality
      • 5.6.3.9 Installation Type
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Functionality
      • 5.6.4.9 Installation Type
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Functionality
      • 5.6.5.9 Installation Type
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Glycotope
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Argenx
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Xencor
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Mabwell
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 ImmunoGen
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 MacroGenics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Alector
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Zymeworks
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Alligator Bioscience
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 MorphoSys
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sorrento Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genmab
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Crescendo Biologics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Harbour BioMed
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 BioAtla
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us